Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 7Triple Negative Breast Neoplasms 4Ovarian Neoplasms 4Glioblastoma 4Small Cell Lung Carcinoma 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Gliosarcoma 3Fallopian Tube Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Astrocytoma 3Rectal Neoplasms 2Lymphoma, T-Cell 2Lymphoma, Mantle-Cell 2Glioma 2Colorectal Neoplasms 2Brain Neoplasms 2Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Thrombocythemia, Essential 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Sezary Syndrome 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Oropharyngeal Neoplasms 1Oligodendroglioma 1

Interventions

Cisplatin 32human papillomavirus vaccine, L1 type 16, 18 16Brachytherapy 15Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 12Paclitaxel 11Bevacizumab 11pembrolizumab 10Platinum 91,2-diaminocyclohexaneplatinum II citrate 9Topotecan 8Radiotherapy, Intensity-Modulated 8Radiation 8Papillomavirus Vaccines 8atezolizumab 6Gemcitabine 6Fluorodeoxyglucose F18 6Cyclophosphamide 6tisotumab vedotin 5fludarabine phosphate 5fludarabine 5aldesleukin 5Taxes 5Radiotherapy 5Magnetic Resonance Spectroscopy 5Carboplatin 5Vaccines, Synthetic 4Nivolumab 4Immunoglobulin G 4Disulfides 4Colposcopy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Uterine Cervical Neoplasms × veliparib × Clear all
NCT01266447 2019-08-08

Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer

National Cancer Institute (NCI)

Phase 2 Completed
27 enrolled 11 charts
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡